Loading...
XNASMRVI
Market cap756mUSD
Dec 24, Last price  
5.33USD
1D
3.90%
1Q
-34.20%
IPO
-81.62%
Name

Maravai LifeSciences Holdings Inc

Chart & Performance

D1W1MN
XNAS:MRVI chart
P/E
P/S
2.62
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
8.20%
Rev. gr., 5y
18.47%
Revenues
289m
-67.28%
123,833,000143,140,000284,098,000799,240,000883,001,000288,945,000
Net income
-119m
L
-17,731,000-5,201,00076,888,000469,250,000490,663,000-119,029,000
CFO
126m
-76.45%
-186,00024,115,000152,187,000368,570,000535,977,000126,224,000
Earnings
Feb 20, 2025

Profile

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
IPO date
Nov 20, 2020
Employees
660
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
288,945
-67.28%
883,001
10.48%
799,240
181.33%
Cost of revenue
166,023
187,326
155,780
Unusual Expense (Income)
NOPBT
122,922
695,675
643,460
NOPBT Margin
42.54%
78.79%
80.51%
Operating Taxes
756,111
60,809
61,515
Tax Rate
615.11%
8.74%
9.56%
NOPAT
(633,189)
634,866
581,945
Net income
(119,029)
-124.26%
490,663
4.56%
469,250
510.30%
Dividends
Dividend yield
Proceeds from repurchase of equity
(20)
2,358
1,709
BB yield
0.00%
-0.06%
-0.02%
Debt
Debt current
12,853
11,709
9,722
Long-term debt
684,934
631,378
528,313
Deferred revenue
Other long-term liabilities
11,984
693,375
754,547
Net debt
114,266
(413)
(13,778)
Cash flow
Cash from operating activities
126,224
535,977
368,570
CAPEX
(65,553)
(17,090)
(14,850)
Cash from investing activities
(122,310)
(267,612)
105,655
Cash from financing activities
(61,090)
(187,499)
(159,049)
FCF
(673,252)
551,991
532,206
Balance
Cash
574,962
632,138
551,272
Long term investments
8,559
11,362
541
Excess cash
569,074
599,350
511,851
Stockholders' equity
661,381
767,345
416,975
Invested Capital
843,761
1,583,501
1,415,848
ROIC
42.33%
46.92%
ROCE
8.70%
31.87%
35.11%
EV
Common stock shares outstanding
131,919
255,323
257,803
Price
6.55
-54.23%
14.31
-65.85%
41.90
49.38%
Market cap
864,069
-76.35%
3,653,672
-66.18%
10,801,946
298.46%
EV
1,351,466
4,013,284
11,018,030
EBITDA
171,703
733,778
668,212
EV/EBITDA
7.87
5.47
16.49
Interest
45,892
20,414
30,260
Interest/NOPBT
37.33%
2.93%
4.70%